Univercells Technologies and Repligen announced a collaboration to incorporate Repligen’s MAVEN® Real Time Glucose Control Platform into Univercells’ scale-X bioreactors. This integration enables continuous, noninvasive measurement of glucose and lactate levels during adherent cell cultures for viral vector and vaccine production. Enhanced real-time bioprocess analytics allow manufacturers to optimize media, feeding, and control strategies dynamically, with data updates as frequent as every two minutes. The partnership aims to simplify advanced therapy manufacturing by merging complementary technologies, facilitating improved process control and scalability for commercial biologics production.